


What is claimed is:

1. A compound selected from the group of compounds represented by formula (I):



wherein:

A is $-(CR_2)_n$ where n is 1, 2, or 3 and R is independently hydrogen or alkyl;

B is aryl or heteroaryl;

X and Y are, independently, CH or nitrogen;

10 R¹ is alkyl, alkenyl, cyanoalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaralkyl, heterocycl, heterocyclalkyl, heteroalkyl or alkylcarbonylalkyl;

R² is alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, hydroxyalkyl, alkoxyalkyl, alkoxy carbonylalkyl, or NR¹³R¹⁴ wherein:

R¹³ is hydrogen or alkyl;

15 R¹⁴ is hydrogen, alkyl, alkenyl, acyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aralkyl, hydroxyalkyl, alkoxyalkyl, carboxyalkyl, alkoxy carbonylalkyl, or aminoalkyl;

R³ is hydrogen, alkyl, halo, nitro, cyano, hydroxy, alkoxy; and prodrugs, individual isomers, mixtures of isomers, and pharmaceutically acceptable salts

20 thereof.

Sub B1

2. The compound of Claim 1, wherein:

R³ is hydrogen; and

X and Y are both CH.

*Sub
B1*

3. The compound of Claim 2 wherein B is aryl.
4. The compound of Claim 3 wherein B is optionally substituted phenyl.

5

5. The compound of Claim 4 wherein R¹ is alkyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl or heteroalkyl.

*D 2
cont*

10

6. The compound of Claim 5 wherein R¹ is heteroalkyl.

10

7. The compound of Claim 6 wherein R¹ is alkylsulfonylalkyl.

10

8. The compound of Claim 7 wherein R² is alkyl.

15

9. The compound of Claim 8 wherein A is -(CH₂)-.

15

10. The compound of Claim 7 wherein R² is NR¹³R¹⁴ wherein R¹³ and R¹⁴ are hydrogen.

15

11. The compound of Claim 10 wherein A is -(CH₂)-.

20

12. The compound of Claim 2 wherein B is heteroaryl.

*Sub
B2*

13. The compound of Claim 12 wherein R¹ is alkyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl or heteroalkyl.

*D 3
25
cont*

14. The compound of Claim 13 wherein R¹ is heteroalkyl.

15. The compound of Claim 14 wherein R¹ is alkylsulfonylalkyl.

30

16. The compound of Claim 15 wherein R² is alkyl.

17. The compound of Claim 16 wherein A is $-(\text{CH}_2)-$.

18. The compound of Claim 15 wherein R^2 is $\text{NR}^{13}\text{R}^{14}$ wherein R^{13} and R^{14} are hydrogen.

19. The compound of Claim 18 wherein A is $-(\text{CH}_2)-$.

20. The compound of Claim 1, wherein:
 R^3 is hydrogen; and
one of X and Y is N.

21. The compound of Claim 20 wherein B is aryl.

22. The compound of Claim 21 wherein B is optionally substituted phenyl.

23. The compound of Claim 22 wherein R^1 is alkyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl or heteroalkyl.

24. The compound of Claim 23 wherein R^1 is heteroalkyl.

25. The compound of Claim 24 wherein R^1 is alkylsulfonylalkyl.

26. The compound of Claim 25 wherein R^2 is alkyl.

27. The compound of Claim 26 wherein A is $-(\text{CH}_2)-$.

28. The compound of Claim 25 wherein R^2 is $\text{NR}^{13}\text{R}^{14}$ wherein R^{13} and R^{14} are hydrogen.

29. The compound of Claim 28 wherein A is $-(\text{CH}_2)-$.

30

D 2
30. The compound of Claim 20 wherein B is heteroaryl.

31. The compound of Claim 30 wherein R¹ is alkyl, cycloalkyl, cycloalkyl-alkyl, heterocyclyl, heterocyclylalkyl or heteroalkyl.

cont
32. The compound of Claim 31 wherein R¹ is heteroalkyl.

33. The compound of Claim 32 wherein R¹ is alkylsulfonylalkyl.

10 34. The compound of Claim 33 wherein R² is alkyl.

35. The compound of Claim 34 wherein A is -(CH₂)-.

15 36. The compound of Claim 33 wherein R¹ is NR¹³R¹⁴ wherein R¹³ and R¹⁴ are hydrogen.

37. The compound of Claim 36 wherein A is -(CH₂)-.

D 3
20 38. The compound of Claim 1 wherein:

R¹ is alkylsulfonylalkyl;

B is aryl; and

X and Y are CH.

39. The compound of Claim 38, wherein R² is alkyl.

cont
25 40. The compound of Claim 39, wherein A is -(CH₂)-.

41. The compound of Claim 38, wherein R² is NH₂.

42. The compound of Claim 41, wherein A is -(CH₂)-.

43. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable excipient.

44. A method of treatment of a disease in a mammal treatable by administration of a prostaglandin G/H synthase inhibitor, comprising administration to the mammal a therapeutically effective amount of a compound of Claim 1.

D3
cont

5

45. The method of Claim 44, wherein the disease is an inflammatory disease.

10 46. The method of Claim 45, wherein the inflammatory disease is selected from myositis, synovitis, arthritis (rheumatoid arthritis and osteoarthritis), gout, ankylosing spondylitis and bursitis.

15 47. The method of Claim 44, wherein the disease is Alzheimer's disease.

48. The method of Claim 44, wherein the disease is an autoimmune disease.

16 49. The method of Claim 48, wherein the autoimmune disease is selected from systemic lupus erythematosus and type I diabetes.

20

* * * * *

add
by

25